Clinical trial Recruiting at 1 site Interventional Ages 18 and up Men only

Intraoperative Lidocaine or Dexmedetomidine to Help Postoperative Pain After Urethral Reconstruction

Official title: Effects of Intravenous Lidocaine and Dexmedetomidine Infusions on Postoperative Pain and the Development of Chronic Pain Following Urethral Reconstruction Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial.

Run by Centre of Postgraduate Medical Education · NCT07676942 · Data updated 2026-11-12

This study tests whether giving lidocaine or dexmedetomidine during urethral reconstruction can reduce pain after surgery and lower the chance of long-lasting pain.

Quick facts

Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment80 (estimated)
SponsorCentre of Postgraduate Medical Education
Academic / other
Locations1 site (Warsaw)
StatusRecruiting
StartedJuly 7, 2026
Main results expectedJune 2028
Study endsJuly 2028
Registry record updatedOctober 9, 2026
Trial IDNCT07676942 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-75 scheduled for urethral reconstructive surgery, ASA I-III, able to consent, without known drug allergies to lidocaine or dexmedetomidine.

Probably not a fit

Patients with contraindications to lidocaine or dexmedetomidine, chronic pain conditions, or ongoing use of opioids, gabapentinoids, or antidepressants may not benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized approach compares perioperative intravenous lidocaine, dexmedetomidine, and placebo during urethral reconstructive surgery. It aims to measure postoperative pain intensity, recovery quality, and the development of chronic postoperative pain, including neuropathic features. The protocol uses established dosing within standard practice to assess potential benefits in pain modulation and opioid-sparing effects. Eligible participants are adults aged 18-75 with ASA I-III status undergoing urethral reconstruction. Outcomes will inform whether perioperative pharmacologic strategies can reduce the transition from acute to chronic pain in this surgical population.

Why it matters

Potential benefit: If successful, patients may experience lower acute pain, faster recovery, and a reduced risk of chronic postoperative pain after urethral reconstruction.

How similar studies have gone: Prior perioperative use of lidocaine and dexmedetomidine for analgesia has shown pain-reduction and opioid-sparing effects in various surgeries, though data specific to urethral reconstruction and CPP prevention remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ASA status less or equal 3
* Scheduled for reconstructive surgery of urethra
* Able to understand information provided and to sign informed consent for participation in the study

Exclusion Criteria:

* known allergy to one of the investigated medications
* current chronic pain
* known chronic use of opioids, gabapentinoids and antidepressants

Where it's running

  • Department of Anesthesiology and Intensive Care, Centre of Postgraduate Medical Education
    Warsaw, Poland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.